Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Saredutant (SR48968C), saredutant (SR48968), Saredutant succinate (SR48968C)
Saredutant · 13 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Saredutant 100mg and Paroxetine 20 mg | EXPERIMENTAL | combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks |
| Saredutant 30mg and Paroxetine 20mg | EXPERIMENTAL | combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks |
| Paroxetine 20 mg and saredutant placebo | ACTIVE_COMPARATOR | paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase |
| Saredudant/Escitalopram | EXPERIMENTAL | Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks |
| Placebo and Escitalopram | ACTIVE_COMPARATOR | Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks |
| Saredutant 100 mg | EXPERIMENTAL | Saredudant100 mg once daily for a maximum of 32 weeks |
| Escitalopram 10 mg | ACTIVE_COMPARATOR | Escitalopram 10 mg once daily for a maximum of 32 weeks |
| Saredutant 30 mg | EXPERIMENTAL | Saredutant 30 mg once daily for a maximum of 8 weeks |
| Name | Type | Description |
|---|---|---|
| saredutant (SR48968) | DRUG | oral administration,capsules |
| paroxetine | DRUG | oral administration, capsules |
| placebo | DRUG | oral administration, capsules |
| escitalopram | DRUG | oral administration, capsules |
| Saredutant | DRUG | - |
| Saredutant (SR48968C) | DRUG | oral administration (capsules) |
| Saredutant succinate (SR48968C) | DRUG | - |
Inclusion Criteria: * Outpatients with recurrent Major Depressive Disorder Exclusion Criteria: * Symptoms of current depressive episode for less than 30 days or more than 2 years * Mild depression, as measured by standard clinical research scales * Significant suicide risk * Lack of sexual activi...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2 | PHASE3 | DT120 |
| Vistagen Therapeutics, Inc. | VTGN | 3 | PHASE3 | Fasedienol |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | VQW-765 |
| AbbVie, Inc. | ABBV | 1 | PHASE2 | ABBV-932 |
| Psyence Biomedical Ltd. | PBM | 1 | PHASE2 | Psilocybin therapy |
Saredutant is an investigational drug that was studied for major depressive disorder, generalized anxiety disorder, and other depressive and anxiety conditions. It was developed by Sanofi and reached Phase 3 clinical testing. It is not an approved treatment; all eight of its registered trials are completed.
Saredutant targets TACR2, also known as the neurokinin-2 receptor. It acts as an antagonist at this receptor, meaning it blocks receptor activity. This mechanism was investigated for potential effects in mood and anxiety disorders, though the drug remains investigational.
Saredutant was developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the clinical development program, including Phase 3 trials in major depressive disorder and generalized anxiety disorder. No other developer is listed for this asset.
Saredutant reached Phase 3 clinical development. All eight of its registered trials are completed, and none are currently active. It is an investigational drug and has not been approved for any indication.
Saredutant has been studied in eight completed trials, including NCT00629551 testing it with paroxetine for major depressive disorder, NCT00531622 with escitalopram for major depressive disorder, NCT00429260 evaluating abrupt discontinuation in depression, and NCT00417118 in generalized anxiety disorder. All trials are completed.
Yes, Saredutant is also known as SR48968C, SR48968, and saredutant succinate (SR48968C). These names refer to the same investigational compound developed by Sanofi for psychiatric indications.